Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;5(5):578-84.
doi: 10.3978/j.issn.2072-1439.2012.02.05.

VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer

Xiuyi Zhi  1 , Wen Gao, Baohui Han, Yue Yang, Hui Li, Deruo Liu, Changli Wang, Gong Min, Hao Long, James R Rigas, Mark Carey, Thierry Jahan, Amanda Sammann, Joseph Reza, Daoyuan Wang, Michael J Mann, David M Jablons, Jianxing He; China Clinical Trials Consortium
Affiliations

VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer

Xiuyi Zhi et al. J Thorac Dis. 2013 Oct.

Abstract

Background: To evaluate the safety and tolerability of docetaxel/carboplatin regimen in the post-operative setting of patients with non-small cell lung cancer (NSCLC).

Methods: Enrolment of 133 patients with stage Ib - IIIa NSCLC was undertaken in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. The primary endpoint of the study was safety, as reflected by a febrile neutropenia rate of <10%. Other endpoints assessed protocol compliance and the impact of minimally invasive surgical technique.

Results: Patient accrual was completed at 1 center in the US and 10 centers in China in <6 months. Febrile neutropenia complicated treatment in 12 patients (9.0%), below the predetermined safety threshold of 14 patients. Four VATS and 8 open thoracotomy patients experienced febrile neutropenia (P=0.26). Completion of the three-cycle adjuvant regimen was achieved in 86% (95% CI, 77-95%) of patients. Sixty-two of 66 VATS patients compared to 53 of 67 open thoracotomy patients received all three doses according to protocol (P<0.01). Thirteen serious adverse events (9.8%) and no deaths were attributed to the study regimen.

Conclusions: In this rapidly accrued study, docetaxel and carboplatin were well-tolerated in the adjuvant treatment of NSCLC. Adjuvant treatment compliance was higher among patients undergoing a minimally invasive surgical approach. (ClinicalTrials.gov number NCT00883675).

Keywords: Non-small cell lung cancer; adjuvant chemotherapy; carboplatin; docetaxel.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Zhao Y, Kosorok MR, Zeng D. Reinforcement learning design for cancer clinical trials. Stat Med 2009;28:3294-315 - PMC - PubMed
    1. Shao W, Wang D, He J.The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis 2010;2:89-99 - PMC - PubMed
    1. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9 - PubMed
    1. Voon PJ, Chul Cho B, Yeo WL, et al. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. J Thorac Dis 2010;2:144-53 - PMC - PubMed
    1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909 - PMC - PubMed

Associated data